Search results
Results from the WOW.Com Content Network
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on ... The company raised $26 million and began trading as ALNY on the Nasdaq stock ...
In this article we will take a look at whether hedge funds think Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a good investment right now. We check hedge fund and billionaire investor sentiment ...
Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.
The stock of Alnylam Pharmaceuticals (NAS:ALNY, 30-year Financials) appears to be possible value trap, according to GuruFocus Value calculation.
Alnylam (ALNY) delivered earnings and revenue surprises of -46.94% and 8.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our ...
Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. [1] microRNA explained
The company's shares have climbed more than 70% since it disclosed early results of the late-stage study of the drug, vutrisiran, in June. Vutrisiran was tested in patients with transthyretin ...